Navigation Links
ViroPharma to Present at Several Upcoming Healthcare Conferences
Date:9/3/2009

EXTON, Pa., Sept. 3 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the company will be presenting in four upcoming healthcare investment conferences during the month of September.

Charles Rowland, vice president and chief financial officer of ViroPharma, will present at the Rodman & Renshaw 11th Annual Global Healthcare Conference at 11:15 A.M. ET on Thursday, September 10, 2009. The conference is being held at the New York Palace Hotel.

Vincent Milano, president and chief executive officer of ViroPharma, will present at the Thomas Weisel Partners 2009 Global Healthcare Conference at 8:00 A.M. ET on Thursday, September 10, 2009. The conference is being held at the Four Seasons Hotel in Boston.

William Roberts, vice president, corporate communications will present at the BioCentury Newsmakers in the Biotech Industry Conference at 3:30 P.M. ET on Wednesday, September 16, 2009. The conference is being held at the Millennium Broadway Hotel in New York City.

Mr. Milano will also present at the ThinkEquity 6th Annual Growth Conference at 5:15 P.M. ET (2:15 P.M. PT) on Wednesday, September 16, 2009. The conference is being held at the St. Regis Hotel in San Francisco.

ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1 esterase inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
2. ViroPharma to Present at Two June Healthcare Conferences
3. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
4. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
5. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
6. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
7. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
8. ViroPharma to Present at Three November Healthcare Conferences
9. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
10. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
11. ViroPharma to Present at Three October Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
Breaking Biology Technology:
(Date:6/27/2016)... Research and Markets has announced the addition of the ... offering. The report forecasts the ... at a CAGR of 12.28% during the period 2016-2020. ... analysis with inputs from industry experts. The report covers the market ... also includes a discussion of the key vendors operating in this ...
(Date:6/22/2016)... -- The American College of Medical Genetics and Genomics was once ... one of the fastest-growing trade shows during the Fastest 50 ... Las Vegas . Winners ... each of the following categories: net square feet of paid ... The 2015 ACMG Annual Meeting was ranked 23 out of ...
(Date:6/22/2016)... 2016   Acuant , the leading ... has partnered with RightCrowd ® to ... Management, Self-Service Kiosks and Continuous Workforce Assurance. ... functional enhancements to existing physical access control ... with an automated ID verification and authentication ...
Breaking Biology News(10 mins):